Comparison · NCT00069160-sae
Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 vs Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 vs Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22: serious adverse events. Trial comparisons, record NCT00069160-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00069160-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.261 | 0.125 | 0.465 | wilson | |
| Risk in group 2 | 0.32 | 0.172 | 0.516 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0591 | -0.297 | 0.193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.815 | 0.333 | 1.99 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.214 | 2.63 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 than on Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22 | 16.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 | Patients receive 40 mg/m\^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m\^2 docetaxel was administered every 21 days in combination with a single 150 mg dose. | 6 | 23 | EG000 |
| Group 2 | Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22 | Patients receive 40 mg/m\^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m\^2 docetaxel was administered every 21 days in combination with a single 150 mg dose. | 8 | 25 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 4 years and 11 months
Source ClinicalTrials.gov
Trial
- Title
- Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
- NCT number
- NCT00069160
- Phases
- PHASE2
- Conditions
- Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
- Interventions
- docetaxel, tariquidar, 99mTc-sestamibi imaging
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2012-10-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00069160?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00069160-sae